Cumberland Pharmaceuticals, Inc.

Nashville, TN 37203

Market Performance

NASDAQ: CPIX
Market Cap $119 Million
52 Week High $7.61
52 Week Low $4.87

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $1.79MM
First Award Date 09/30/04
Most Recent Award Date 09/01/16

Key Personnel

Last Name Name Awards Contact
Lane Kirk B Lane 2
Cleary John D Cleary 1
Goldfarb Adam N. Goldfarb 1
Hallahan Dennis E Hallahan 1
Lew Dukhee Betty Lew 1
FREEMAN MICHAEL L. FREEMAN 1
MANNING HENRY CHARLES MANNING 1

8 Awards Won

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-15-270
Budget: 09/01/16 - 08/31/17

? DESCRIPTION (provided by applicant): Problem: Lower gastrointestinal bleeding is a significant medical problem in the United States, accounting for more than 120,000 hospital admissions and tens of billions of dollars of healthcare spending annually. It is common for bleeding from a single site to stop and restart multiple times. The three...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-13-235
Budget: 09/22/14 - 08/31/15

DESCRIPTION (provided by applicant): There is an urgent, unmet need for novel therapeutic approaches that are efficacious against lung cancer. Ranking first among cancer deaths in the U.S., this disease has 5-year relative survival rates of <20%. Most lung cancers are non-small cell (NSCLC, 85% of cases). Curative surgery is not an option for t...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-11-097
Budget: 05/01/12 - 04/30/13

DESCRIPTION (provided by applicant): A strong unmet need exists to develop new treatments for anemias associated with chronic disease states, collectively referred to as anemia of chronic inflammation (ACI). ACI is highly prevalent in the U.S. and makes a large contribution to public morbidity and mortality. Despite billions of dollars spent ann...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 09/21/09 - 08/31/11

DESCRIPTION (provided by applicant): Roughly 500,000 cancer patients are treated with radiotherapy each year. Acute and late sequelae of radiotherapy have a negative impact upon the quality of life of cancer survivors. These sequelae include proctitis, cystitis, esophageal stricture, cutaneous fibrosis plus others. We propose a novel means of pr...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 02/01/09 - 01/31/11

DESCRIPTION (provided by applicant): The long-term goal of this application is to develop mannan derived from Baker's yeast as asthma therapy. The limitations of currently available immunomodulators are their toxicity at higher doses and the lack of beneficial effect on airway smooth muscle (ASM) remodeling and therefore, new adjunctive therapeu...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/05 - 08/31/09

DESCRIPTION (provided by applicant): Approximately 50,000 cancer patients a year have recurrent fluid accumulation in the space between their chest wall and lung. This condition is called malignant pleural effusion (MPE). This fluid impairs breathing and worsens the quality of life in these patients. The current treatments are not ideal and incl...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 04/15/05 - 03/31/06

DESCRIPTION (provided by applicant): Cumberland Pharmaceuticals and the University of Mississippi Mycotic Research Centers' long-term goal will be to improve anti-fungal pharmacotherapy particularly for patients with human immunodeficiency infections (HIV). We are jointly developing a high purity amphotericin B (AmB HP) product for intravenous...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/04 - 08/31/05

DESCRIPTION (provided by applicant): Approximately 50,000 cancer patients a year have recurrent fluid accumulation in the space between their chest wall and lung. This condition is called malignant pleural effusion (MPE). This fluid impairs breathing and worsens the quality of life in these patients. The current treatments are not ideal and incl...